290 related articles for article (PubMed ID: 11208689)
1. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
Aikawa M; Rabkin E; Sugiyama S; Voglic SJ; Fukumoto Y; Furukawa Y; Shiomi M; Schoen FJ; Libby P
Circulation; 2001 Jan; 103(2):276-83. PubMed ID: 11208689
[TBL] [Abstract][Full Text] [Related]
2. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits.
Fukumoto Y; Libby P; Rabkin E; Hill CC; Enomoto M; Hirouchi Y; Shiomi M; Aikawa M
Circulation; 2001 Feb; 103(7):993-9. PubMed ID: 11181475
[TBL] [Abstract][Full Text] [Related]
3. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.
Luan Z; Chase AJ; Newby AC
Arterioscler Thromb Vasc Biol; 2003 May; 23(5):769-75. PubMed ID: 12663370
[TBL] [Abstract][Full Text] [Related]
4. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis.
Ganné F; Vasse M; Beaudeux JL; Peynet J; François A; Mishal Z; Chartier A; Tobelem G; Vannier JP; Soria J; Soria C
Thromb Haemost; 2000 Oct; 84(4):680-8. PubMed ID: 11057870
[TBL] [Abstract][Full Text] [Related]
5. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Shiomi M; Ito T
Br J Pharmacol; 1999 Feb; 126(4):961-8. PubMed ID: 10193776
[TBL] [Abstract][Full Text] [Related]
6. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits.
Suzuki H; Kobayashi H; Sato F; Yonemitsu Y; Nakashima Y; Sueishi K
J Atheroscler Thromb; 2003; 10(2):109-16. PubMed ID: 12740485
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits.
Mitani H; Egashira K; Kimura M
Pharmacol Res; 2003 Nov; 48(5):417-27. PubMed ID: 12967585
[TBL] [Abstract][Full Text] [Related]
8. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
Nagashima H; Aoka Y; Sakomura Y; Sakuta A; Aomi S; Ishizuka N; Hagiwara N; Kawana M; Kasanuki H
J Vasc Surg; 2002 Jul; 36(1):158-63. PubMed ID: 12096274
[TBL] [Abstract][Full Text] [Related]
9. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.
Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G
Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280
[TBL] [Abstract][Full Text] [Related]
10. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
11. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Denoyelle C; Vasse M; Körner M; Mishal Z; Ganné F; Vannier JP; Soria J; Soria C
Carcinogenesis; 2001 Aug; 22(8):1139-48. PubMed ID: 11470741
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical pharmacology of cerivastatin.
Bischoff H; Heller AH
Am J Cardiol; 1998 Aug; 82(4B):18J-25J. PubMed ID: 9737642
[TBL] [Abstract][Full Text] [Related]
13. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Pauletto P; Puato M; Faggin E; Sartore S
J Vasc Res; 2000; 37(3):189-94. PubMed ID: 10859477
[TBL] [Abstract][Full Text] [Related]
15. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth.
Igarashi M; Takeda Y; Mori S; Ishibashi N; Komatsu E; Takahashi K; Fuse T; Yamamura M; Kubo K; Sugiyama Y; Saito Y
Br J Pharmacol; 1997 Mar; 120(6):1172-8. PubMed ID: 9134232
[TBL] [Abstract][Full Text] [Related]
16. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma.
Aikawa M; Libby P
Ann N Y Acad Sci; 2000 May; 902():140-52. PubMed ID: 10865834
[TBL] [Abstract][Full Text] [Related]
17. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects.
Park JK; Müller DN; Mervaala EM; Dechend R; Fiebeler A; Schmidt F; Bieringer M; Schäfer O; Lindschau C; Schneider W; Ganten D; Luft FC; Haller H
Kidney Int; 2000 Oct; 58(4):1420-30. PubMed ID: 11012877
[TBL] [Abstract][Full Text] [Related]
18. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
[TBL] [Abstract][Full Text] [Related]
20. Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition.
Bischoff H; Angerbauer R; Boberg M; Petzinna D; Schmidt D; Steinke W; Thomas G
Atherosclerosis; 1998 Sep; 139 Suppl 1():S7-13. PubMed ID: 9811153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
